0001615774-17-001110.txt : 20170316 0001615774-17-001110.hdr.sgml : 20170316 20170316203127 ACCESSION NUMBER: 0001615774-17-001110 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20170314 FILED AS OF DATE: 20170316 DATE AS OF CHANGE: 20170316 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SECOND SIGHT MEDICAL PRODUCTS INC CENTRAL INDEX KEY: 0001266806 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 000000000 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12744 SAN FERNANDO ROAD, BLDG. 3 CITY: SYLMAR STATE: CA ZIP: 91342 BUSINESS PHONE: 818-833-5000 MAIL ADDRESS: STREET 1: 12744 SAN FERNANDO ROAD, BLDG. 3 CITY: SYLMAR STATE: CA ZIP: 91342 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PFEFFER MATTHEW J CENTRAL INDEX KEY: 0001192063 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36747 FILM NUMBER: 17696200 4 1 s105599_form4.xml OWNERSHIP DOCUMENT X0306 4 2017-03-14 0 0001266806 SECOND SIGHT MEDICAL PRODUCTS INC EYES 0001192063 PFEFFER MATTHEW J 28903 NORTH AVENUE PAINE VALENCIA CA 91355 1 0 0 0 COMMON STOCK 2017-03-14 2017-03-14 4 A 0 5582 1.47 A 23043 D Warrant to Purchase Common Stock 1.47 2017-03-14 4 A 0 5582 A 2017-03-14 2022-03-14 Common Stock 5582 5582 D Mr. Pfeffer acquired common stock and warrants reported on this Form 4 pursuant to an exercise of subscription rights previously distributed by the Company to all holders of the Company's common stock. Each stockholder received a right to invest $0.47 for every share held of record on February 10, 2017, the record date, to purchase units consisting of one share of common stock and one warrant to purchase one share of common stock. The final allocations of units were confirmed on March 14, 2017. * Power-of-Attorney, attached as exhibit. /s/ Tom Miller by Power-of-Attorney* 2017-03-16 EX-24.1 2 s105599_241.htm EXHIBIT 24.1

Exhibit 24.1

 

POWER OF ATTORNEY

(FOR EXECUTING FORM ID, FORMS 3, 4 AND 5 AND SCHEDULES 13D AND 130)

 

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Tom Miller and Scott Dunbar, or either of them, signing individually, the undersigned's true and lawful attorneys-in-fact and agents to:

 

(i)   prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the Securities and Exchange Commission of reports required by Section 13(d) and Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or any rules or regulations promulgated thereunder;

 

(ii)   prepare, execute and file, for and on behalf of the undersigned with respect to holdings of and transactions in securities issued by a company to the undersigned or Second Sight Medical Products, Inc. any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Exchange Act, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 130 and Schedule 130 (or any successor schedules or forms adopted under the Exchange Act) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

 

(iii)   take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

 

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact in serving in such capacity at the request of the undersigned, are not assuming, nor is Second Sight Medical Products, Inc. assuming, any of the undersigned's responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

 

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned's holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact shall no longer be employed by (or ceases to be a Director of) Second Sight Medical Products, Inc.

 

I hereby declare that any act or thing lawfully done hereunder by the foregoing attorneys-in-fact shall be binding on the undersigned as if done by myself.

 

 

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 8th day of June, 2015.

GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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